Advertisement
Advertisement
IMNM
Immunome, Inc.
18.71
USDSponsored
+0.80
+4.50%
Nov 06, 15:59 UTC -5
Closed
After-Market
19.15
+0.44
+2.35%
Immunome, Inc. (IMNM) Earnings
IMNM Earnings Reports
Positive Surprise Ratio
IMNM beat 8 of 23 last estimates.
35%
Next Report
Date of Next Report
Nov 16, 2026
Estimate for Q3 26 (Revenue/ EPS)
$145.72K
/-$0.64
Implied change from Q2 26 (Revenue/ EPS)
--
/-1.54%
Implied change from Q3 25 (Revenue/ EPS)
--
/-1.54%
Immunome, Inc. earnings per share and revenue
On Aug 11, 2026, IMNM reported earnings of -0.65 USD per share (EPS) for Q2 26, missing the estimate of -0.53 USD, resulting in a -22.04% surprise. Revenue reached --, compared to an expected 185.46 thousand, with a -100.00% difference. The market reacted with a +6.63% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 11 analysts forecast an EPS of -0.64 USD, with revenue projected to reach 145.72 thousand USD, implying an decrease of -1.54% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
FAQ
What were Immunome, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Immunome, Inc. reported EPS of -$0.65, missing estimates by -22.04%, and revenue of $0.00, -100% below expectations.
How did the market react to Immunome, Inc.'s Q2 2026 earnings?
The stock price moved up 6.63%, changed from $26.25 before the earnings release to $27.99 the day after.
When is Immunome, Inc. expected to report next?
The next earning report is scheduled for Nov 16, 2026.
What are the forecasts for Immunome, Inc.'s next earnings report?
Based on 11
analysts, Immunome, Inc. is expected to report EPS of -$0.64 and revenue of $145.72K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.